ProCE Banner Activity

PURPOSE 1: PrEP Adherence and Persistence With Twice Yearly LEN Injections vs Daily Oral PrEP

Conference Coverage
Slideset

In PURPOSE 1, higher annual persistence rates observed among cisgender women receiving every-6-month injectable LEN vs daily oral FTC/TAF or FTC/TDF PrEP.

Released: November 20, 2024

Expiration: November 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare